Solid Biosciences Inc. SLDB Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Private Placement
Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Private Placement at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement.
The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Solid Biosciences Inc.'s proceeds from issuance of common stock and pre funded warrants in private placement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Solid Biosciences Inc.'s proceeds from issuance of common stock and pre funded warrants in private placement?
- Solid Biosciences Inc. (SLDB) reported proceeds from issuance of common stock and pre funded warrants in private placement of $239.97M in Q1 2026.
- What does proceeds from issuance of common stock and pre funded warrants in private placement mean?
- This captures the cash inflows from private equity placements, including common stock and pre-funded warrants, outside of public market offerings. It reflects the company's ability to secure targeted funding from institutional or strategic investors. This is a critical metric for assessing alternative liquidity sources for clinical-stage companies.